• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin.

作者信息

Şahin Mustafa, Miskioğlu Mine, İnanır Işıl, Akar Hikmet, Neşe Nalan, Temiz Peyker, Aydoğdu İsmet

机构信息

Celal Bayar University Faculty of Medicine, Department of Internal Medicine, Manisa, Turkey

Celal Bayar University Faculty of Medicine, Department of Hematology, Manisa, Turkey

出版信息

Turk J Haematol. 2021 Feb 25;38(1):85-87. doi: 10.4274/tjh.galenos.2020.2020.0512. Epub 2020 Dec 16.

DOI:10.4274/tjh.galenos.2020.2020.0512
PMID:33504137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7927435/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1da/7927435/922cf8099181/TJH-38-85-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1da/7927435/68f7d91ada9e/TJH-38-85-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1da/7927435/358c04953df9/TJH-38-85-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1da/7927435/922cf8099181/TJH-38-85-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1da/7927435/68f7d91ada9e/TJH-38-85-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1da/7927435/358c04953df9/TJH-38-85-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1da/7927435/922cf8099181/TJH-38-85-g3.jpg

相似文献

1
Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin.皮肤间变性大细胞淋巴瘤对维布妥昔单抗有显著反应
Turk J Haematol. 2021 Feb 25;38(1):85-87. doi: 10.4274/tjh.galenos.2020.2020.0512. Epub 2020 Dec 16.
2
Brentuximab vedotin in multifocal cutaneous anaplastic large cell lymphoma in a patient with human immunodeficiency virus following Hodgkin lymphoma.在一名霍奇金淋巴瘤后感染人类免疫缺陷病毒的患者中，用本妥昔单抗治疗多灶性皮肤间变性大细胞淋巴瘤。
Clin Exp Dermatol. 2019 Jul;44(5):562-564. doi: 10.1111/ced.13824. Epub 2018 Nov 14.
3
Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report.皮损内注射维布妥昔单抗成功治疗原发性皮肤间变性大细胞淋巴瘤：一例报告
Int J Dermatol. 2022 Jul;61(7):e267-e269. doi: 10.1111/ijd.15834. Epub 2021 Aug 7.
4
Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.本妥昔单抗在一名接受血液透析患者中的成功应用：首例真实病例经验
Clin Lymphoma Myeloma Leuk. 2019 Nov;19(11):e595-e596. doi: 10.1016/j.clml.2019.07.443. Epub 2019 Aug 30.
5
[Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma].[本妥昔单抗用于既往未经治疗的系统性间变性大细胞淋巴瘤]
Bull Cancer. 2021 Jan;108(1):12-13. doi: 10.1016/j.bulcan.2020.10.004. Epub 2020 Dec 10.
6
RF - Brentuximab as Treatment for CD30 Primary Cutaneous Lymphoma.利妥昔单抗 - 本妥昔单抗治疗CD30原发性皮肤淋巴瘤
Actas Dermosifiliogr (Engl Ed). 2019 Nov;110(9):769-770. doi: 10.1016/j.ad.2018.03.025. Epub 2019 May 28.
7
Isolated Central Nervous System Progression During Systemic Treatment With Brentuximab Vedotin Monotherapy in a Pediatric Patient With Recurrent ALK-negative Anaplastic Large Cell Lymphoma.在接受 Brentuximab Vedotin 单药治疗的儿童复发性 ALK 阴性间变性大细胞淋巴瘤患者中，孤立性中枢神经系统进展。
J Pediatr Hematol Oncol. 2021 Aug 1;43(6):e864-e866. doi: 10.1097/MPH.0000000000001914.
8
rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma.艾滋病相关ALK阴性间变性大细胞淋巴瘤中的重排
BMJ Case Rep. 2019 Sep 30;12(9):e230641. doi: 10.1136/bcr-2019-230641.
9
Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy.本妥昔单抗单药治疗改善皮肤间变性大细胞淋巴瘤
Turk J Haematol. 2018 May 25;35(2):135-136. doi: 10.4274/tjh.2017.0448. Epub 2018 Feb 2.
10
Early and sustained remission with brentuximab vedotin in a case of disseminated cutaneous relapse from systemic anaplastic large cell lymphoma refractory to chemotherapy.在一例对化疗难治的系统性间变性大细胞淋巴瘤皮肤播散性复发患者中，使用本妥昔单抗实现早期且持续缓解。
Eur J Dermatol. 2017 Dec 1;27(6):671-673. doi: 10.1684/ejd.2017.3149.

引用本文的文献

1
Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.抗 CD30 抗体药物偶联物治疗淋巴瘤：现有知识、尚存争议和未来展望。
Ann Hematol. 2023 Jan;102(1):13-29. doi: 10.1007/s00277-022-05054-9. Epub 2022 Dec 13.

本文引用的文献

1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.贝林妥欧单抗联合化疗治疗 CD30 阳性外周 T 细胞淋巴瘤（ECHELON-2）：一项全球性、双盲、随机、3 期临床试验。
Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4.
2
Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy.本妥昔单抗单药治疗改善皮肤间变性大细胞淋巴瘤
Turk J Haematol. 2018 May 25;35(2):135-136. doi: 10.4274/tjh.2017.0448. Epub 2018 Feb 2.
3
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
本妥昔单抗维达妥或医师选择治疗 CD30 阳性皮肤 T 细胞淋巴瘤（ALCANZA）：一项国际性、开放性标签、随机、3 期、多中心试验。
Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7.
4
Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.原发性皮肤淋巴瘤：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2013 Oct;24 Suppl 6:vi149-54. doi: 10.1093/annonc/mdt242. Epub 2013 Jul 17.
5
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.本妥昔单抗维迪昔（SGN-35）治疗复发或难治性系统性间变大细胞淋巴瘤患者的Ⅱ期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.